ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer

被引：0
|
作者：
Hanker, Ariella B.
Estrada, Monica Valeria
Zhao, Junfei
Cheng, Feixiong
Moore, Preston D.
Tyson, Darren
Sanchez, Violeta
Rexer, Brent N.
Sanders, Melinda
Zhao, Zhongming
Stricker, Thomas P.
Arteaga, Carlos L.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-302
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
302
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination
    Balz, Lydia M.
    Bartkowiak, Kai
    Andreas, Antje
    Pantel, Klaus
    Niggemann, Bernd
    Zaenker, Kurt S.
    Brandt, Burkhard H.
    Dittmar, Thomas
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 234 - 244
  • [22] HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
    Ruiz-Saenz, Ana
    Dreyer, Courtney
    Campbell, Marcia R.
    Steri, Veronica
    Gulizia, Nate
    Moasser, Mark M.
    CANCER RESEARCH, 2018, 78 (13) : 3645 - 3658
  • [23] Targeting HER2 and PI3K in Uterine Serous Cancer
    Diver, E. J.
    Hernandez, S. F.
    Scaltriti, M.
    Rueda, B. R.
    Growdon, W. B.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 596 - 596
  • [24] mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
    Elkabets, Moshe
    Vora, Sadhna
    Juric, Dejan
    Morse, Natasha
    Mino-Kenudson, Mari
    Muranen, Taru
    Tao, Jessica
    Campos, Ana Bosch
    Rodon, Jordi
    Ibrahim, Yasir H.
    Serra, Violeta
    Rodrik-Outmezguine, Vanessa
    Hazra, Saswati
    Singh, Sharat
    Kim, Phillip
    Quadt, Cornelia
    Liu, Manway
    Huang, Alan
    Rosen, Neal
    Engelman, Jeffrey A.
    Scaltriti, Maurizio
    Baselga, Jose
    SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (196)
  • [25] Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
    Poovassery, Jayakumar S.
    Kang, Jeffrey C.
    Kim, Dongyoung
    Ober, Raimund J.
    Ward, E. Sally
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 267 - 277
  • [26] Clinical Trial of Alpelisib and Tucatinib in Patients with PIK3CA-Mutant HER2-Positive Metastatic Breast Cancer
    Shagisultanova, Elena
    Wisinski, Kari B.
    Gawryletz, Chelsea D.
    Datko, Farrah M.
    Medgyesy, Diana
    Diamond, Jennifer R.
    Borges, Virginia F.
    Kabos, Peter
    CANCER RESEARCH, 2023, 83 (05)
  • [27] Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
    Mayer I.A.
    Current Breast Cancer Reports, 2015, 7 (4) : 210 - 214
  • [28] Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
    Brachmann, Saskia M.
    Hofmann, Irmgard
    Schnell, Christian
    Fritsch, Christine
    Wee, Susan
    Lane, Heidi
    Wang, Shaowen
    Garcia-Echeverria, Carlos
    Maira, Sauveur-Michel
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (52) : 22299 - 22304
  • [29] A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors.
    Garrett, Joan T.
    Sutton, Cammie R.
    Bialucha, Carl Uli
    Ettenberg, Seth A.
    Wallweber, Jerry
    DeFazio-Eli, Lisa
    Arteaga, Carlos L.
    CANCER RESEARCH, 2013, 73 (08)
  • [30] CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
    Vora, Sadhna R.
    Juric, Dejan
    Kim, Nayoon
    Mino-Kenudson, Mari
    Huynh, Tiffany
    Costa, Carlotta
    Lockerman, Elizabeth L.
    Pollack, Sarah F.
    Liu, Manway
    Li, Xiaoyan
    Lehar, Joseph
    Wiesmann, Marion
    Wartmann, Markus
    Chen, Yan
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Kim, Sunkyu
    Schlegel, Robert
    Huang, Alan
    Engelman, Jeffrey A.
    CANCER CELL, 2014, 26 (01) : 136 - 149
12345